Scarica l'app Stockscreener
4.88
0.20%
-0.010
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
CAPR 2-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline - PR Newswire
2 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. - GlobeNewswire
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress - The Manila Times
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND - Business Wire
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future - StocksToTrade
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure - Yahoo Finance
Axsome Therapeutics shares gain 2% as strong sales growth offsets Q2 miss - Yahoo Finance
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ... - Yahoo Finance
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - PR Newswire
Akebia Therapeutics Announces Initiation of a Phase 2 - GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 3 - GlobeNewswire
Cullinan Therapeutics Announces Positive End-of-Phase 1 - GlobeNewswire
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Slips 2% as Resistance Holds Firm: Key Levels to WatchDouble Bottom - careplusvn.com
Beam Therapeutics to Present Updated Data from Phase 1/2 - GlobeNewswire
LB Pharmaceuticals Announces Accelerated Timing of Topline - GlobeNewswire
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries - GlobeNewswire
Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn - The Hindu
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
Diagonal Therapeutics Announces First Patient Dosed in - GlobeNewswire
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
Spero Therapeutics and Innovent Biologics Announce - GlobeNewswire
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress - GlobeNewswire
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis - GlobeNewswire
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of - GlobeNewswire
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - Yahoo Finance
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know - Yahoo Finance
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Nuo Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Oncotelic Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Intellia Therapeutics, Inc. SEC Filing (Jul 2, 2026) | NTLA Form 144 - Stock Titan
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
BioRestorative Therapies Announces Completion of BRTX-100 - GlobeNewswire
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma - PR Newswire
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):